Explore 3 Stock Ideas & Industry Insights Download Free Report
● Full-year adjusted earnings guidance rose to $0.44 to $0.48 a share.
● Proceeds will help repay at least $750 million ofCreditFacilityborrowings.
● The 2026Revenueforecast rose to $115 million to $117 million.
● DoubleU Games holds roughly two-thirds of the company.
● The new drug application is on track for the first half of 2027.
● JPMorgan flagged promotional competition as a concern.
● Dole's update arrived as investors favored riskier stocks over defensive ones.
● Milestone payments could reach about $134 million.
● It has shipped over 8 million microinverters from US facilities.
Key Highlights● Eupraxia climbed on November 9 after RBC initiated coverage.● The rating is Outperform with a $14 price target.● The shares rose to about $6.89.● An interim EP-104GI readout is expected in December.A bullish first lookEupraxia Pharmaceuticals (NASDAQ:EPRX) climbed on Monday, November 9, …
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…